KiOmed Pharma and moveUP Partner to Develop and Market a Companion Healthcare Application for Personalised Treatment of Osteoarthritis

3 June 2021

Liège-Herstal, Belgium, June 3 2021 – Belgian biotech company KiOmed Pharma and digital therapeutics company moveUP are pleased to announce the signature of an exclusive agreement for the development and licensing of a unique mobile health companion application dedicated to personalised conservative intra-articular treatment for patients suffering from osteoarthritis. This application is to be developed by moveUP, while exclusive global marketing rights are to be granted to KiOmed, who will market it alongside their innovative single-shot intra-articular injection for the treatment of knee osteoarthritis

We are excited to join forces with moveUP in revolutionising the personalised treatment of osteoarthritis, an incurable debilitating pathology affecting hundreds of millions of patients worldwide,’ states KiOmed Pharma Executive Chairman Mr. François Blondel. He concludes that,‘This partnership further demonstrates the huge potential of Belgium’s life science industry’.

moveUP will develop the app using its innovative healthcare platform on which CE-approved digital therapies can be developed and rolled-out. Some of moveUP’s solutions have already been reimbursed in Belgium and/or funded by various private insurers.  Through this agreement, moveUP will grant KiOmed global rights to market this personalised healthcare app across selected markets either itself or via its distributors. They will then be entitled to any upfront, milestone and sales-related payments.

We are excited by this opportunity to expand our digital therapy approach to the conservative treatment of osteoarthritis, wherein we believe the potential for improved patient outcomes is high. We are convinced that our combined expertise will lead to finding a solution with high value for both physicians and patients alike,’ states moveUP Director Mr Charles-Eric Winandy.

KiOmed and moveUP plan to assess Q3’s new app this year in several leading clinical centres, first in Belgium, before extending the evaluation program to the Netherlands, France, Germany and the rest of Europe. The two companies also agreed to establish a joint business model that will best leverage and fairly redistribute any added value generated from this exclusive collaboration.

We are delighted to have agreed this strategic partnership with moveUP, which represents a major step towards a more personalised and cost-effective treatment of patients with osteoarthritis’states KiOmed Pharma CEO Dr Houtaï Choumane. He adds,‘We strongly believe that this innovative app will further leverage clinical utility and differentiation for our KiOmedine® single-shot injection for the benefit of physicians and patients suffering from osteoarthritis’.

About KiOmed Pharma

KiOmed Pharma is a Belgium-based biotech spin-off of world-leading bio-chemical company Kitozyme. KiOmed Pharma focuses on the development, manufacturing and marketing of safe and effective medical devices and therapeutic solutions based on KiOmedine®, an innovative and exclusive animal-free chitosan biodegradable biopolymer. KiOmed Pharma offers a unique pipeline of products for tackling invalidating osteoarthritis, skin aging and dry eye syndrome.

About moveUP

moveUP is a digital therapeutics company uniquely combining both the development of medical technologies and the provision of care. Founded in 2015 by two engineers, a lawyer and an orthopaedic surgeon, the company develops data-driven personalised remote digital care for post-acute out-patients, delivering similar clinical outcomes at a lower cost, while enabling healthcare professionals to focus on more complex patients or urgent situations. It does so by providing validated and (semi)-automated value-based treatment plans on an integrated multi-modal platform, managed by local care teams and supported by moveUP’s virtual clinic, providing 24/7 expert support. moveUP has offices in Brussels and Ghent. The company employs 25 people and recently announced a capital increase to realise its global technological ambitions. For more information, visit